Adverum Biotechnologies (ADVM) Competitors $2.38 +0.13 (+5.53%) Closing price 07/3/2025 02:21 PM EasternExtended Trading$2.33 -0.05 (-2.31%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM vs. CRGX, CYBN, EDIT, EPRX, ENGN, TLSA, CTMX, OGI, GNFT, and FDMTShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include CARGO Therapeutics (CRGX), Cybin (CYBN), Editas Medicine (EDIT), Eupraxia Pharmaceuticals (EPRX), enGene (ENGN), Tiziana Life Sciences (TLSA), CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Its Competitors CARGO Therapeutics Cybin Editas Medicine Eupraxia Pharmaceuticals enGene Tiziana Life Sciences CytomX Therapeutics Organigram Global GENFIT 4D Molecular Therapeutics CARGO Therapeutics (NASDAQ:CRGX) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends. Which has preferable valuation and earnings, CRGX or ADVM? Adverum Biotechnologies has higher revenue and earnings than CARGO Therapeutics. CARGO Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCARGO TherapeuticsN/AN/A-$167.50M-$4.62-0.97Adverum Biotechnologies$1M49.82-$130.93M-$6.40-0.37 Does the media favor CRGX or ADVM? In the previous week, Adverum Biotechnologies had 2 more articles in the media than CARGO Therapeutics. MarketBeat recorded 2 mentions for Adverum Biotechnologies and 0 mentions for CARGO Therapeutics. CARGO Therapeutics' average media sentiment score of 0.00 equaled Adverum Biotechnologies'average media sentiment score. Company Overall Sentiment CARGO Therapeutics Neutral Adverum Biotechnologies Neutral Do insiders and institutionals believe in CRGX or ADVM? 93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 2.9% of CARGO Therapeutics shares are owned by insiders. Comparatively, 6.0% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, CRGX or ADVM? CARGO Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Is CRGX or ADVM more profitable? CARGO Therapeutics' return on equity of -45.93% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets CARGO TherapeuticsN/A -45.93% -39.58% Adverum Biotechnologies N/A -130.53%-66.31% Do analysts prefer CRGX or ADVM? CARGO Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 235.57%. Adverum Biotechnologies has a consensus target price of $23.80, indicating a potential upside of 897.90%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe Adverum Biotechnologies is more favorable than CARGO Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CARGO Therapeutics 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryAdverum Biotechnologies beats CARGO Therapeutics on 9 of the 13 factors compared between the two stocks. Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.82M$2.89B$5.53B$9.02BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-0.3721.7127.7020.25Price / Sales49.82283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book0.707.538.035.65Net Income-$130.93M-$55.14M$3.18B$249.15M7 Day Performance10.93%4.22%2.88%2.91%1 Month Performance-15.72%0.91%1.67%4.11%1 Year Performance-65.38%5.40%34.39%20.98% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies4.0838 of 5 stars$2.39+5.5%$23.80+897.9%-65.4%$49.82M$1M-0.37190CRGXCARGO Therapeutics1.4841 of 5 stars$4.12-1.7%$15.00+264.1%-70.9%$193.20MN/A-0.89116Positive NewsCYBNCybin3.1208 of 5 stars$8.39+2.9%$86.00+925.0%N/A$193.17MN/A-1.9250News CoverageAnalyst RevisionEDITEditas Medicine4.1882 of 5 stars$2.20-3.5%$4.70+113.6%-43.7%$190.87M$32.31M-0.72230EPRXEupraxia Pharmaceuticals2.4518 of 5 stars$5.76+8.7%$11.00+91.0%+117.3%$190.57MN/A-7.5829Gap UpHigh Trading VolumeENGNenGene2.774 of 5 stars$3.64-0.5%$23.29+539.7%-57.6%$187.04MN/A-2.2131TLSATiziana Life Sciences0.6646 of 5 stars$1.58-1.3%N/A+85.5%$186.96MN/A0.008Positive NewsCTMXCytomX Therapeutics3.8297 of 5 stars$2.27+0.9%$5.33+134.9%+93.0%$181.40M$138.10M4.73170OGIOrganigram Global0.5316 of 5 stars$1.35flatN/A-10.4%$180.82M$117.47M13.50860News CoverageGNFTGENFIT1.9744 of 5 stars$3.73+3.2%$13.00+249.0%-8.2%$180.49M$67.00M0.00120Positive NewsFDMT4D Molecular Therapeutics2.27 of 5 stars$3.71-3.4%$29.56+696.6%-80.6%$177.89M$40K-1.17120 Related Companies and Tools Related Companies CRGX Alternatives CYBN Alternatives EDIT Alternatives EPRX Alternatives ENGN Alternatives TLSA Alternatives CTMX Alternatives OGI Alternatives GNFT Alternatives FDMT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADVM) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
